EichorEICHOR
Condition: Relapsed Refractory Chronic Lymphocytic Leukemia Synced from ClinicalTrials.gov · August 06, 2026

Recruiting studies: Relapsed Refractory Chronic Lymphocytic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
EARLY_Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT06890494Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Phase 3 · 5 location(s) · Newave Pharmaceutical Inc · NCT07342478Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2
Phase 2 · 36 location(s) · AstraZeneca · NCT07024706Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compar
Phase 3 · 192 location(s) · BeOne Medicines · NCT06943872Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Le
Phase 2 · 8 location(s) · National Cancer Institute (NCI) · NCT07061951Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL o
Phase 1/Phase 2 · 24 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT05791409Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed o
Phase 1 · 1 location(s) · University Health Network, Toronto · NCT05963217Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Phase 1/Phase 2 · 1 location(s) · Jennifer R. Brown, MD, PhD · NCT06644183CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
Phase 2 · 16 location(s) · University of Birmingham · NCT03899337Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Phase 1/Phase 2 · 1 location(s) · Medical University of South Carolina · NCT05702853Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small L
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07194980Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Phase 2 · 11 location(s) · Ascentage Pharma Group Inc. · NCT05147467Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refracto
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT04223765A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/Phase 2 · 7 location(s) · CRISPR Therapeutics AG · NCT05643742211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Le
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03670966Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Phase 1 · 9 location(s) · Ascentage Pharma Group Inc. · NCT04215809A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/S
Phase 1 · 14 location(s) · Ono Pharmaceutical Co., Ltd. · NCT06547528A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 · 62 location(s) · Nurix Therapeutics, Inc. · NCT05131022A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisoca
Phase N/A · 1 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06788639A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymp
Phase 2 · 35 location(s) · Nurix Therapeutics, Inc. · NCT07221500Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Phase 1/Phase 2 · 2 location(s) · University Hospital Heidelberg · NCT03676504CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT04186520Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Phase 1/Phase 2 · 18 location(s) · Ascentage Pharma Group Inc. · NCT04494503A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R)
Phase 3 · 55 location(s) · Merck Sharp & Dohme LLC · NCT05947851
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.